Compare MUX & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MUX | VTYX |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 990.9M |
| IPO Year | N/A | 2021 |
| Metric | MUX | VTYX |
|---|---|---|
| Price | $23.80 | $13.87 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 7 |
| Target Price | ★ $21.63 | $13.50 |
| AVG Volume (30 Days) | 1.3M | ★ 5.6M |
| Earning Date | 11-06-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $166,453,000.00 | N/A |
| Revenue This Year | $3.15 | N/A |
| Revenue Next Year | $43.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.38 | $0.78 |
| 52 Week High | $24.88 | $25.00 |
| Indicator | MUX | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 69.84 | 75.76 |
| Support Level | $21.65 | $7.08 |
| Resistance Level | $23.00 | $13.90 |
| Average True Range (ATR) | 1.26 | 0.41 |
| MACD | 0.36 | 0.25 |
| Stochastic Oscillator | 79.97 | 82.20 |
McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.